Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 2,336 matching trials from the live ClinicalTrials.gov search.
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Duarte, California
Conditions
Glioma of Brain
Interventions
Topotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Central Nervous System Tumors, Brain Tumors
Interventions
Gallium-67 Citrate (Ga-67), In-111 DTPA (In-111 pentetate)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Glioma of Brain, Craniopharyngioma, Ependymoma, Germ Cell Tumor
Interventions
Memantine, Placebo, Cognitive Assessment
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Recurrent Visual Pathway Glioma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Refractory Visual Pathway Glioma
Interventions
Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Conditions
Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme, Pediatric Brain Tumor, Recurrent, Pediatric Brain Tumor
Interventions
CMV-DCs with GM-CSF, Td (tetanus toxoid)
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
0 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Brain Metastases
Interventions
Surgery, LITT
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Recurrent Oligodendroglioma, Progressive Oligodendroglioma
Interventions
TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Brain Metastases
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique
Drug · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Glioblastoma Multiforme
Interventions
Atezolizumab + FSRT radiation
Combination Product
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Interventions
LUTATHERA® (Lutetium Lu 177 dotatate)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more
Conditions
Brain and Central Nervous System Tumors
Interventions
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
271
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more
Conditions
Brain Metastasis, Neoplasm
Interventions
Radiosurgery dose escalation
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Central Nervous System Neoplasm, Leptomeningeal Neoplasm, Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
Interventions
Electronic Health Record Review, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Glioblastoma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Brain Cancer
Interventions
Virtual Reality System, Word Search Puzzles
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Duarte, California
Conditions
Brain Tumor
Interventions
Intra-operative Ommaya Reservoir placement
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Brain Cancer, Brain Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 20 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Brain Metastases
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
RRx-001, Temozolomide, Irinotecan
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain Cancer, Prostate Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Recruiting Not applicable Interventional Accepts healthy volunteers

Drinking, Acetate, and Stress

NCT06584448
Conditions
Alcohol Use Disorder, Alcohol Use, Unspecified, Heavy Drinker, Alcohol Use Disorder, Moderate, in Sustained Remission
Interventions
Deuterium Metabolic Imaging with deuterated acetate tracer
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
2
States / cities
New Haven, Connecticut